KLK3 and posterior cortical atrophy: For men diagnosed with Gleason ≤6 tumours and classified as low risk (PSA < 10 ng/ml and stage ≤ T2a), the mortality from PCa over a 10‐ to 15‐year period, even without any intervention, is less than 3%,9 and therefore the risks of treatment often outweigh the benefits.